Science & Tech 20 August 2026
Moderna and Merck’s Personalized mRNA Cancer Vaccine Achieves Success in Phase 3 Trial
Why in the News?
American biotechnology companies Moderna and Merck announced positive Phase 3 clinical trial (INTerpath-001) results for their personalized mRNA-based cancer vaccine (Intismeran Autogene), combined with the immunotherapy drug Keytruda, in treating severe melanoma (skin cancer).
Key Features / Major Points:
Personalized Approach: Unlike traditional vaccines, it is custom-made based on the specific genetic mutations and up to 34 neoantigens identified in a patient's tumor using Artificial Intelligence (AI).
Combination with Keytruda: Administered alongside Merck’s immunotherapy drug Keytruda, significantly reducing the risk of cancer recurrence and distant metastasis following surgical resection.
Mechanism of Action: The mRNA instructs the patient's T-cells to recognize and target specific cancer cells, delivering a dual-strike against residual tumors.
Trial Scope: The INTerpath-001 trial evaluated 1,137 patients with high-risk stage III/IV melanoma who had undergone surgical tumor removal.
Static GK Facts:
mRNA (Messenger RNA) Technology:
Function: Delivers genetic code to cellular machinery to produce specific target proteins.
Prominence: Gained global recognition during the COVID-19 pandemic for rapid vaccine development by Pfizer-BioNTech and Moderna.
Melanoma:
Definition: The most serious type of skin cancer that develops in melanocytes (pigment-producing cells).
One-Liner Quiz (All Competitive Exams):
What type of cancer was primarily targeted in the Phase 3 trial of Moderna and Merck's personalized mRNA vaccine?
Answer: Melanoma (Skin Cancer)
What are the specific tumor-specific mutated proteins called that are identified using AI for personalized mRNA cancer vaccines?
Answer: Neoantigens